跳至主要内容
临床试验/ACTRN12616001533482
ACTRN12616001533482尚未招募4 期

Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in 2 sentinel sites in Indonesia

Ministry of Health of Indonesia0 个研究点目标入组 352 人开始时间: 2016年11月7日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
入组人数
352

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
1 Years 至 65 Years(—)
性别
All

入选标准

  • 1.age between one year to 65 years old, excluding female minors aged 12 to 17 years;
  • 2.mono-infection with P. falciparum or P. vivax detected by microscopy;
  • 3.parasitaemia of more than 500 asexual parasites per microliter for P. falciparum and 250 asexual parasites per microliter P.vivax
  • 4.presence of axillary temperature greater or equal to 37.5 degrees C or history of fever during the past 24 h;
  • 5.ability to swallow oral medication;
  • 6.ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
  • 7.informed assent from any minor participant aged from 12 to 17 years (age of majority in the country); and
  • 8.consent for pregnancy testing from female of child-bearing potential and from their parent or guardian if under the age of majority years.

排除标准

  • 1.presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO;
  • 2.weight under 5 kg;
  • 3.mixed or mono-infection with another Plasmodium species detected by microscopy;
  • 4.presence of severe malnutrition defined as a child aged 6-60 months has a mid-upper arm circumference below 115 mm);
  • 5.presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
  • 6.regular medication, which may interfere with antimalarial pharmacokinetics;
  • 7.history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s); and
  • 8.a positive pregnancy test or breastfeeding (include this criterion only if adults are included)
  • 9.unable to or unwilling to take pregnancy test or to use contraception for women of child-bearing age and who are sexually active.

研究者

相似试验

尚未招募
4 期
Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in 6 sentinel sites in IndonesiaInfection - Studies of infection and infectious agentsMalaria
ACTRN12614000753651Ministry of Health1,200
已完成
4 期
Efficacy and safety of dihydroartemisinin-piperaquine (DP) in Pailin, Preah Vihear and Rattanakiri, and artesunate-mefloquine (ASMQ) in Preah Vihear for uncomplicated P. falciparum malaria and chloroquine (CQ) for P.vivax malaria in the above 3 sites, Cambodia, 2009Infection - Other infectious diseasesMalaria
ACTRN12612000183886Institude Paster du Cambodge420
已完成
4 期
Efficacy and safety of Dihydroartemisinin-Piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in District Headquarter Hospital Zhob of Balochistan province and Tehsil HQ Hospital Sadda Kurram Agency FATA, PakistaMalaria
ACTRN12615001248550Directorate of Malaria Control, Ministry of National Health Services Regulations and Coordination, NIH, Islamabad176
已完成
4 期
Efficacy and safety of dihydroartemisinin+piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Bosaso, Puntland, Somalia.Malaria
ACTRN12616000553471Ministry of Health of Puntland88
已完成
4 期
Efficacy and safety of dihydroaretemisinin+piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Jamame (Lower Juba) Janale (Lower Shabelle) and Jowhar (Middle Shabelle) sites, Somalia.Malaria
ACTRN12616001005448Abdullahi Mohamed Hassan264